Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis
Purpose Chemotherapy-induced nausea and vomiting (CINV) commonly occurs after chemotherapy, adversely affecting patients’ quality of life. Recently, studies have shown inconsistent antiemetic effects of two common 5-hydroxytryptamine 3 receptor antagonists, namely, palonosetron and granisetron. Ther...
Gespeichert in:
| Veröffentlicht in: | European journal of clinical pharmacology 2021-11, Vol.77 (11), p.1597-1609 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1609 |
|---|---|
| container_issue | 11 |
| container_start_page | 1597 |
| container_title | European journal of clinical pharmacology |
| container_volume | 77 |
| creator | Hsu, Yu-Chen Chen, Ching-Yao Tam, Ka-Wai Hsu, Chin-Yu |
| description | Purpose
Chemotherapy-induced nausea and vomiting (CINV) commonly occurs after chemotherapy, adversely affecting patients’ quality of life. Recently, studies have shown inconsistent antiemetic effects of two common 5-hydroxytryptamine 3 receptor antagonists, namely, palonosetron and granisetron. Therefore, we conducted a meta-analysis to evaluate the effectiveness of palonosetron versus granisetron in preventing CINV.
Methods
Relevant studies were obtained from PubMed, Embase, and Cochrane databases. The primary outcome was the complete response (CR) rate. Secondary outcomes were headache and constipation events.
Results
In total, 12 randomized controlled trials and five retrospective studies were reviewed. Palonosetron was consistently statistically superior to granisetron in all phases in terms of the CR rate (acute phases: odds ratio [OR] = 1.28, 95% confidence interval [CI] = 1.06–1.54; delayed phases: OR = 1.38, 95% CI = 1.13–1.69; and overall phases: OR = 1.37, 95% CI = 1.17–1.60). Moreover, a non-significant difference was found between the two groups in terms of the headache event, but the occurrence of the constipation event was lower in the granisetron group than in the palonosetron group.
Conclusion
Palonosetron showed a higher protective efficacy in all phases of CINV prevention, especially in delayed phases, and no relatively severe adverse effects were observed. |
| doi_str_mv | 10.1007/s00228-021-03157-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2528437337</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2583693757</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-8cba3a3d388a41ab4052b6113c489c2927674629c85ecc44234bcc48a5ee30c13</originalsourceid><addsrcrecordid>eNp9kc2KFDEURoMoTk_rC7iQgBs30SQ39edOhtERBtzoukilbvVkqErK3Koe-iV8ZtPTrYILIXDh5nxfAoexV0q-U1JW70lKrWshtRISVFEJ_YRtlAEtlDTqKdvIvBZlU8kLdkl0L6UqGgnP2QVA0wAY2LCf18OAbvF7DEjE48BnO8YQCZcUA99jopX4Ltngzysf-Jww84sPO-7ucIrLHSY7H4QP_eqw58GuhJbb0PN9nPwR_MAtpwMtONnFO54LPD48EhMuVthgxwN5esGeDXYkfHmeW_b90_W3qxtx-_Xzl6uPt8IZoxZRu86ChR7q2hplOyML3ZVKgTN143Sjq7IypW5cXaDLEQ2my7O2BSJIp2DL3p565xR_rEhLO3lyOI42YFyp1YWuDVSQz5a9-Qe9j2vK_z1SNZQNVMWR0ifKpUiUcGjn5CebDq2S7dFWe7LVZlvto61W59Drc_XaTdj_ifzWkwE4AZSvwg7T37f_U_sLESeicg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2583693757</pqid></control><display><type>article</type><title>Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Hsu, Yu-Chen ; Chen, Ching-Yao ; Tam, Ka-Wai ; Hsu, Chin-Yu</creator><creatorcontrib>Hsu, Yu-Chen ; Chen, Ching-Yao ; Tam, Ka-Wai ; Hsu, Chin-Yu</creatorcontrib><description>Purpose
Chemotherapy-induced nausea and vomiting (CINV) commonly occurs after chemotherapy, adversely affecting patients’ quality of life. Recently, studies have shown inconsistent antiemetic effects of two common 5-hydroxytryptamine 3 receptor antagonists, namely, palonosetron and granisetron. Therefore, we conducted a meta-analysis to evaluate the effectiveness of palonosetron versus granisetron in preventing CINV.
Methods
Relevant studies were obtained from PubMed, Embase, and Cochrane databases. The primary outcome was the complete response (CR) rate. Secondary outcomes were headache and constipation events.
Results
In total, 12 randomized controlled trials and five retrospective studies were reviewed. Palonosetron was consistently statistically superior to granisetron in all phases in terms of the CR rate (acute phases: odds ratio [OR] = 1.28, 95% confidence interval [CI] = 1.06–1.54; delayed phases: OR = 1.38, 95% CI = 1.13–1.69; and overall phases: OR = 1.37, 95% CI = 1.17–1.60). Moreover, a non-significant difference was found between the two groups in terms of the headache event, but the occurrence of the constipation event was lower in the granisetron group than in the palonosetron group.
Conclusion
Palonosetron showed a higher protective efficacy in all phases of CINV prevention, especially in delayed phases, and no relatively severe adverse effects were observed.</description><identifier>ISSN: 0031-6970</identifier><identifier>EISSN: 1432-1041</identifier><identifier>DOI: 10.1007/s00228-021-03157-2</identifier><identifier>PMID: 33993343</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Antiemetics - therapeutic use ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Biomedical and Life Sciences ; Biomedicine ; Chemotherapy ; Clinical trials ; Constipation ; Granisetron - adverse effects ; Granisetron - therapeutic use ; Headache ; Humans ; Meta-analysis ; Nausea ; Nausea - chemically induced ; Nausea - drug therapy ; Palonosetron - adverse effects ; Palonosetron - therapeutic use ; Pharmacology/Toxicology ; Quality of Life ; Randomized Controlled Trials as Topic ; Review ; Serotonin ; Serotonin 5-HT3 Receptor Antagonists - therapeutic use ; Vomiting ; Vomiting - chemically induced ; Vomiting - drug therapy</subject><ispartof>European journal of clinical pharmacology, 2021-11, Vol.77 (11), p.1597-1609</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-8cba3a3d388a41ab4052b6113c489c2927674629c85ecc44234bcc48a5ee30c13</citedby><cites>FETCH-LOGICAL-c441t-8cba3a3d388a41ab4052b6113c489c2927674629c85ecc44234bcc48a5ee30c13</cites><orcidid>0000-0001-6940-0633</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00228-021-03157-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00228-021-03157-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33993343$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hsu, Yu-Chen</creatorcontrib><creatorcontrib>Chen, Ching-Yao</creatorcontrib><creatorcontrib>Tam, Ka-Wai</creatorcontrib><creatorcontrib>Hsu, Chin-Yu</creatorcontrib><title>Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis</title><title>European journal of clinical pharmacology</title><addtitle>Eur J Clin Pharmacol</addtitle><addtitle>Eur J Clin Pharmacol</addtitle><description>Purpose
Chemotherapy-induced nausea and vomiting (CINV) commonly occurs after chemotherapy, adversely affecting patients’ quality of life. Recently, studies have shown inconsistent antiemetic effects of two common 5-hydroxytryptamine 3 receptor antagonists, namely, palonosetron and granisetron. Therefore, we conducted a meta-analysis to evaluate the effectiveness of palonosetron versus granisetron in preventing CINV.
Methods
Relevant studies were obtained from PubMed, Embase, and Cochrane databases. The primary outcome was the complete response (CR) rate. Secondary outcomes were headache and constipation events.
Results
In total, 12 randomized controlled trials and five retrospective studies were reviewed. Palonosetron was consistently statistically superior to granisetron in all phases in terms of the CR rate (acute phases: odds ratio [OR] = 1.28, 95% confidence interval [CI] = 1.06–1.54; delayed phases: OR = 1.38, 95% CI = 1.13–1.69; and overall phases: OR = 1.37, 95% CI = 1.17–1.60). Moreover, a non-significant difference was found between the two groups in terms of the headache event, but the occurrence of the constipation event was lower in the granisetron group than in the palonosetron group.
Conclusion
Palonosetron showed a higher protective efficacy in all phases of CINV prevention, especially in delayed phases, and no relatively severe adverse effects were observed.</description><subject>Antiemetics - therapeutic use</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Constipation</subject><subject>Granisetron - adverse effects</subject><subject>Granisetron - therapeutic use</subject><subject>Headache</subject><subject>Humans</subject><subject>Meta-analysis</subject><subject>Nausea</subject><subject>Nausea - chemically induced</subject><subject>Nausea - drug therapy</subject><subject>Palonosetron - adverse effects</subject><subject>Palonosetron - therapeutic use</subject><subject>Pharmacology/Toxicology</subject><subject>Quality of Life</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Review</subject><subject>Serotonin</subject><subject>Serotonin 5-HT3 Receptor Antagonists - therapeutic use</subject><subject>Vomiting</subject><subject>Vomiting - chemically induced</subject><subject>Vomiting - drug therapy</subject><issn>0031-6970</issn><issn>1432-1041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kc2KFDEURoMoTk_rC7iQgBs30SQ39edOhtERBtzoukilbvVkqErK3Koe-iV8ZtPTrYILIXDh5nxfAoexV0q-U1JW70lKrWshtRISVFEJ_YRtlAEtlDTqKdvIvBZlU8kLdkl0L6UqGgnP2QVA0wAY2LCf18OAbvF7DEjE48BnO8YQCZcUA99jopX4Ltngzysf-Jww84sPO-7ucIrLHSY7H4QP_eqw58GuhJbb0PN9nPwR_MAtpwMtONnFO54LPD48EhMuVthgxwN5esGeDXYkfHmeW_b90_W3qxtx-_Xzl6uPt8IZoxZRu86ChR7q2hplOyML3ZVKgTN143Sjq7IypW5cXaDLEQ2my7O2BSJIp2DL3p565xR_rEhLO3lyOI42YFyp1YWuDVSQz5a9-Qe9j2vK_z1SNZQNVMWR0ifKpUiUcGjn5CebDq2S7dFWe7LVZlvto61W59Drc_XaTdj_ifzWkwE4AZSvwg7T37f_U_sLESeicg</recordid><startdate>20211101</startdate><enddate>20211101</enddate><creator>Hsu, Yu-Chen</creator><creator>Chen, Ching-Yao</creator><creator>Tam, Ka-Wai</creator><creator>Hsu, Chin-Yu</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6940-0633</orcidid></search><sort><creationdate>20211101</creationdate><title>Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis</title><author>Hsu, Yu-Chen ; Chen, Ching-Yao ; Tam, Ka-Wai ; Hsu, Chin-Yu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-8cba3a3d388a41ab4052b6113c489c2927674629c85ecc44234bcc48a5ee30c13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antiemetics - therapeutic use</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Constipation</topic><topic>Granisetron - adverse effects</topic><topic>Granisetron - therapeutic use</topic><topic>Headache</topic><topic>Humans</topic><topic>Meta-analysis</topic><topic>Nausea</topic><topic>Nausea - chemically induced</topic><topic>Nausea - drug therapy</topic><topic>Palonosetron - adverse effects</topic><topic>Palonosetron - therapeutic use</topic><topic>Pharmacology/Toxicology</topic><topic>Quality of Life</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Review</topic><topic>Serotonin</topic><topic>Serotonin 5-HT3 Receptor Antagonists - therapeutic use</topic><topic>Vomiting</topic><topic>Vomiting - chemically induced</topic><topic>Vomiting - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hsu, Yu-Chen</creatorcontrib><creatorcontrib>Chen, Ching-Yao</creatorcontrib><creatorcontrib>Tam, Ka-Wai</creatorcontrib><creatorcontrib>Hsu, Chin-Yu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hsu, Yu-Chen</au><au>Chen, Ching-Yao</au><au>Tam, Ka-Wai</au><au>Hsu, Chin-Yu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis</atitle><jtitle>European journal of clinical pharmacology</jtitle><stitle>Eur J Clin Pharmacol</stitle><addtitle>Eur J Clin Pharmacol</addtitle><date>2021-11-01</date><risdate>2021</risdate><volume>77</volume><issue>11</issue><spage>1597</spage><epage>1609</epage><pages>1597-1609</pages><issn>0031-6970</issn><eissn>1432-1041</eissn><abstract>Purpose
Chemotherapy-induced nausea and vomiting (CINV) commonly occurs after chemotherapy, adversely affecting patients’ quality of life. Recently, studies have shown inconsistent antiemetic effects of two common 5-hydroxytryptamine 3 receptor antagonists, namely, palonosetron and granisetron. Therefore, we conducted a meta-analysis to evaluate the effectiveness of palonosetron versus granisetron in preventing CINV.
Methods
Relevant studies were obtained from PubMed, Embase, and Cochrane databases. The primary outcome was the complete response (CR) rate. Secondary outcomes were headache and constipation events.
Results
In total, 12 randomized controlled trials and five retrospective studies were reviewed. Palonosetron was consistently statistically superior to granisetron in all phases in terms of the CR rate (acute phases: odds ratio [OR] = 1.28, 95% confidence interval [CI] = 1.06–1.54; delayed phases: OR = 1.38, 95% CI = 1.13–1.69; and overall phases: OR = 1.37, 95% CI = 1.17–1.60). Moreover, a non-significant difference was found between the two groups in terms of the headache event, but the occurrence of the constipation event was lower in the granisetron group than in the palonosetron group.
Conclusion
Palonosetron showed a higher protective efficacy in all phases of CINV prevention, especially in delayed phases, and no relatively severe adverse effects were observed.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>33993343</pmid><doi>10.1007/s00228-021-03157-2</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0001-6940-0633</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0031-6970 |
| ispartof | European journal of clinical pharmacology, 2021-11, Vol.77 (11), p.1597-1609 |
| issn | 0031-6970 1432-1041 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2528437337 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Antiemetics - therapeutic use Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biomedical and Life Sciences Biomedicine Chemotherapy Clinical trials Constipation Granisetron - adverse effects Granisetron - therapeutic use Headache Humans Meta-analysis Nausea Nausea - chemically induced Nausea - drug therapy Palonosetron - adverse effects Palonosetron - therapeutic use Pharmacology/Toxicology Quality of Life Randomized Controlled Trials as Topic Review Serotonin Serotonin 5-HT3 Receptor Antagonists - therapeutic use Vomiting Vomiting - chemically induced Vomiting - drug therapy |
| title | Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T12%3A47%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20of%20palonosetron%20versus%20granisetron%20in%20preventing%20chemotherapy-induced%20nausea%20and%20vomiting:%20a%20systematic%20review%20and%20meta-analysis&rft.jtitle=European%20journal%20of%20clinical%20pharmacology&rft.au=Hsu,%20Yu-Chen&rft.date=2021-11-01&rft.volume=77&rft.issue=11&rft.spage=1597&rft.epage=1609&rft.pages=1597-1609&rft.issn=0031-6970&rft.eissn=1432-1041&rft_id=info:doi/10.1007/s00228-021-03157-2&rft_dat=%3Cproquest_cross%3E2583693757%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2583693757&rft_id=info:pmid/33993343&rfr_iscdi=true |